Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2021

Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience

(1) , (2) , (1) , , , (3) , (3) , (4) , (5) , (6) , (7, 8, 9, 10) , , (11) , (12) , (13) , (14) , (15) , (16) , (17) , (18) , (19) , (20) , (1, 21) , (22) , (4) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
Alexis Caulier
  • Fonction : Auteur
  • PersonId : 1151781
  • IdRef : 194466000
Murielle Roussel
  • Fonction : Auteur
Pierre Morel
  • Fonction : Auteur
Naelle Lombion
  • Fonction : Auteur
Benoit Branco
  • Fonction : Auteur
Chantal Doyen
  • Fonction : Auteur
Denis Caillot
  • Fonction : Auteur
Bruno Royer
  • Fonction : Auteur

Résumé

Multiple myeloma (MM) is rare in young patients, especially before age 40 years at diagnosis, representing <2% of all patients with MM. Little is known about the disease characteristics and prognosis of these patients. In this study, we examined 214 patients diagnosed with MM at age <= 40 years over 15 years, in the era of modern treatments. Among them, 189 patients had symptomatic MM. Disease characteristics were similar to older patients: 35% had anemia, 17% had renal impairment, and 13% had hypercalcemia. The staging was ISS-1 in 52.4%, ISS-2 in 27.5%, and ISS-3 in 20.1%. Overall, 18% of patients had high-risk cytogenetics [del 17p and/or t(4;14)]. Ninety percent of patients received intensive chemotherapy followed by autologous stem cell transplant, and 25% of patients had allogeneic stem cell transplant predominantly at time of relapse. The median follow-up was 76 months, the estimated median overall survival was 14.5 years, and the median progression free-survival was 41 months. In multivariate analysis, bone lesions (hazard ratio [HR], 3.95; P =.01), high ISS score (HR, 2.14; P =.03), and high-risk cytogenetics (HR, 4.54; P <.0001) were significant risk factors for poor outcomes. Among predefined time-dependent covariables, onset of progression (HR, 13.2; P <.0001) significantly shortened overall survival. At 5 years, relative survival compared with same age- and sexmatched individuals was 83.5%, and estimated standardized mortality ratio was 69.9 (95% confidence interval, 52.7-91.1), confirming that MM dramatically shortens the survival of young patients despite an extended survival after diagnosis.

Dates et versions

hal-03578209 , version 1 (17-02-2022)

Identifiants

Citer

Alexis Caulier, Murielle Roussel, Pierre Morel, Naelle Lombion, Benoit Branco, et al.. Epidemiological landscape of young patients with multiple myeloma diagnosed before 40 years of age: the French experience. Blood, 2021, 138 (25), pp.2686-2695. ⟨10.1182/blood.2021011285⟩. ⟨hal-03578209⟩
35 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More